Karuna Therapeutics, Inc., A Bristol Myers Squibb Company

This study is checking the long-term safety of a drug called KarXT in teenagers (13-17) with schizophrenia, and a combination of KarXT and KarX-EC in children (5-17) with irritability linked to autism. About 400 participants who completed earlier studies will take the drug for up…

This study tests an investigational drug called KarXT to see if it can prevent the return of psychosis (like hallucinations or delusions) in people with Alzheimer's disease. About 410 participants aged 55-90 will receive either KarXT or a placebo for 38 weeks. The main goal is to…

This study looks at the long-term safety of an investigational drug called KarXT when added to current antipsychotic medications for people with schizophrenia. About 280 adults who completed a previous KarXT study will take the drug for up to 52 weeks. Researchers will track side…

This Phase 3 trial tests whether the drug KarXT can safely reduce psychosis (hallucinations and delusions) in people with Alzheimer's disease. About 500 participants aged 55 to 90 with mild to severe Alzheimer's and moderate to severe psychosis will receive either KarXT or a plac…

This study is testing the long-term safety of an experimental drug called KarXT for people with Alzheimer's disease who also experience psychosis (hallucinations or delusions). About 800 participants who completed earlier studies will take KarXT for up to 52 weeks. The main goal …

This phase 3 trial tests whether the drug KarXT can safely reduce psychosis (hallucinations and delusions) in people with mild to severe Alzheimer's disease. About 406 participants aged 55 to 90 will receive either KarXT or a placebo. The study aims to see if the drug improves sy…

This early-stage study is testing whether KarXT, a new drug for schizophrenia, changes how the body processes three other common medications (midazolam, fexofenadine, and digoxin). Sixty healthy adults will take KarXT along with each of these drugs to see if their levels in the b…

This early-stage study looks at how different versions of a liver enzyme (CYP2D6) affect the breakdown of xanomeline, one part of the drug KarXT. About 56 healthy volunteers with four different metabolism types will take KarXT and have their blood tested. The goal is to see if pe…